1uui: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /> <applet load="1uui" size="450" color="white" frame="true" align="right" spinBox="true" caption="1uui" /> '''NMR STRUCTURE OF A SYNTHETIC SMALL MOLECULE...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1uui.gif|left|200px]]<br />
[[Image:1uui.gif|left|200px]]<br /><applet load="1uui" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="1uui" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="1uui" />
caption="1uui" />
'''NMR STRUCTURE OF A SYNTHETIC SMALL MOLECULE, RBT158, BOUND TO HIV-1 TAR RNA'''<br />
'''NMR STRUCTURE OF A SYNTHETIC SMALL MOLECULE, RBT158, BOUND TO HIV-1 TAR RNA'''<br />


==Overview==
==Overview==
The targeting of RNA for the design of novel anti-viral compounds has, until now proceeded largely without incorporating direct input from, structure-based design methodology, partly because of lack of structural, data, and complications arising from substrate flexibility. We propose a, paradigm to explain the physical mechanism for ligand-induced refolding of, trans-activation response element (TAR RNA) from human immunodeficiency, virus 1 (HIV-1). Based upon Poisson-Boltzmann analysis of the TAR, structure, as bound by a peptide derived from the transcriptional, activator protein, Tat, our hypothesis shows that two specific, electrostatic interactions are necessary to stabilise the conformation., This result contradicts the belief that a single argininamide residue is, responsible for stabilising the TAR fold, as well as the conventional, wisdom that electrostatic interactions with RNA are non-specific or, dominated by phosphates. We test this hypothesis by using NMR and, computational methods to model the interaction of a series of novel, inhibitors of the in vitro RNA-binding activities for a peptide derived, from Tat. A subset of inhibitors, including the bis-guanidine compound, rbt203 and its analogues, induce a conformation in TAR similar to that, brought about by the protein. Comparison of the interactions of two of, these ligands with the RNA and structure-activity relationships observed, within the compound series, confirm the importance of the two specific, electrostatic interactions in the stabilisation of the Tat-bound RNA, conformation. This work illustrates how the use of medicinal chemistry and, structural analysis can provide a rational basis for prediction of, ligand-induced conformational change, a necessary step towards the, application of structure-based methods in the design of novel RNA or, protein-binding drugs.
The targeting of RNA for the design of novel anti-viral compounds has until now proceeded largely without incorporating direct input from structure-based design methodology, partly because of lack of structural data, and complications arising from substrate flexibility. We propose a paradigm to explain the physical mechanism for ligand-induced refolding of trans-activation response element (TAR RNA) from human immunodeficiency virus 1 (HIV-1). Based upon Poisson-Boltzmann analysis of the TAR structure, as bound by a peptide derived from the transcriptional activator protein, Tat, our hypothesis shows that two specific electrostatic interactions are necessary to stabilise the conformation. This result contradicts the belief that a single argininamide residue is responsible for stabilising the TAR fold, as well as the conventional wisdom that electrostatic interactions with RNA are non-specific or dominated by phosphates. We test this hypothesis by using NMR and computational methods to model the interaction of a series of novel inhibitors of the in vitro RNA-binding activities for a peptide derived from Tat. A subset of inhibitors, including the bis-guanidine compound rbt203 and its analogues, induce a conformation in TAR similar to that brought about by the protein. Comparison of the interactions of two of these ligands with the RNA and structure-activity relationships observed within the compound series, confirm the importance of the two specific electrostatic interactions in the stabilisation of the Tat-bound RNA conformation. This work illustrates how the use of medicinal chemistry and structural analysis can provide a rational basis for prediction of ligand-induced conformational change, a necessary step towards the application of structure-based methods in the design of novel RNA or protein-binding drugs.


==About this Structure==
==About this Structure==
1UUI is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/ ] with P12 as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1UUI OCA].  
1UUI is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/ ] with <scene name='pdbligand=P12:'>P12</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1UUI OCA].  


==Reference==
==Reference==
Line 17: Line 16:
[[Category: Bower, J.]]
[[Category: Bower, J.]]
[[Category: Davis, B.]]
[[Category: Davis, B.]]
[[Category: Drysdale, M.J.]]
[[Category: Drysdale, M J.]]
[[Category: Karn, J.]]
[[Category: Karn, J.]]
[[Category: Lentzen, G.]]
[[Category: Lentzen, G.]]
[[Category: Murchie, A.I.H.]]
[[Category: Murchie, A I.H.]]
[[Category: Potter, A.J.]]
[[Category: Potter, A J.]]
[[Category: Varani, G.]]
[[Category: Varani, G.]]
[[Category: P12]]
[[Category: P12]]
Line 31: Line 30:
[[Category: tar rna]]
[[Category: tar rna]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Thu Nov  8 14:33:45 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 15:28:28 2008''